The global market for Bioresorbable Vascular Scaffolds was estimated at US$422.5 Million in 2024 and is projected to reach US$640.0 Million by 2030, growing at a CAGR of 7.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Bioresorbable Vascular Scaffolds market.
The growing global prevalence of cardiovascular diseases, coupled with the increasing demand for minimally invasive procedures, has propelled the adoption of bioresorbable vascular scaffolds. Patients and cardiologists are increasingly favoring these devices due to their potential to improve long-term outcomes and reduce the need for repeat interventions. Additionally, advancements in polymer science and bioresorbable metal alloys are enhancing scaffold strength, degradation control, and biocompatibility, making BVS a promising alternative to traditional stents. As healthcare systems prioritize patient-centric and cost-effective solutions, BVS is emerging as a key innovation in interventional cardiology.
Another major breakthrough is the incorporation of drug-eluting coatings that help prevent restenosis by releasing antiproliferative agents such as sirolimus or everolimus during the initial healing phase. These drug-eluting bioresorbable scaffolds have demonstrated promising clinical outcomes by reducing in-stent restenosis rates while ensuring optimal vascular healing. Furthermore, computational modeling and AI-driven optimization techniques are enhancing scaffold design, leading to thinner strut profiles and improved flexibility, which reduce complications such as scaffold thrombosis. As these technological advancements continue to refine BVS performance, the adoption of these next-generation devices is expected to accelerate in interventional cardiology.
Another key trend shaping the market is the increasing regulatory support for bioresorbable scaffolds. While earlier-generation BVS faced concerns over scaffold thrombosis and suboptimal degradation rates, recent innovations in material science and clinical data have led to renewed interest from regulatory agencies and healthcare professionals. Additionally, the expansion of bioresorbable technology beyond coronary interventions - into peripheral artery disease (PAD) and other vascular conditions - is opening new market opportunities. As clinical trials continue to validate the benefits of BVS, and more next-generation devices receive regulatory approvals, the market is poised for significant expansion in both developed and emerging economies.
Another crucial driver shaping the market is the strong investment in research and development (R&D) by medical device companies and academic institutions. Continuous improvements in scaffold design, resorption kinetics, and drug-eluting capabilities are enhancing the clinical feasibility of BVS technology. Additionally, strategic collaborations between healthcare providers, medical institutions, and biotech firms are accelerating the commercialization of advanced bioresorbable scaffolds. The increasing adoption of value-based healthcare models, which prioritize long-term patient benefits over short-term procedural costs, is also expected to boost the demand for BVS. As these factors continue to drive innovation and adoption, bioresorbable vascular scaffolds are set to redefine the future of coronary and peripheral artery disease management, improving patient outcomes while reducing long-term healthcare costs.
Segments: Application (Peripheral Artery Application, Coronary Artery Application); End-Use (Hospitals End-Use, Ambulatory Care Centers (ACS) End-Use, Specialty Clinics End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Bioresorbable Vascular Scaffolds Market - Key Trends & Drivers Summarized
Why Are Bioresorbable Vascular Scaffolds Gaining Momentum in Cardiovascular Treatments?
Bioresorbable vascular scaffolds (BVS) are revolutionizing the treatment of coronary artery disease (CAD) by offering a temporary structural solution that naturally dissolves over time, leaving behind a healed vessel. Unlike traditional metallic stents, which remain permanently in the artery, bioresorbable scaffolds are designed to provide mechanical support during the critical healing phase and then gradually degrade, restoring natural vessel function. This next-generation technology addresses long-term complications associated with permanent stents, such as late-stent thrombosis, vessel caging, and inflammation.The growing global prevalence of cardiovascular diseases, coupled with the increasing demand for minimally invasive procedures, has propelled the adoption of bioresorbable vascular scaffolds. Patients and cardiologists are increasingly favoring these devices due to their potential to improve long-term outcomes and reduce the need for repeat interventions. Additionally, advancements in polymer science and bioresorbable metal alloys are enhancing scaffold strength, degradation control, and biocompatibility, making BVS a promising alternative to traditional stents. As healthcare systems prioritize patient-centric and cost-effective solutions, BVS is emerging as a key innovation in interventional cardiology.
How Are Technological Advancements Improving Bioresorbable Vascular Scaffolds?
Innovations in biomaterials, scaffold design, and drug-eluting technology are driving the evolution of bioresorbable vascular scaffolds, improving their safety, efficacy, and clinical performance. One of the most significant advancements in this field is the development of high-strength bioresorbable polymers, such as poly-L-lactic acid (PLLA), which provide sufficient radial support while ensuring controlled degradation over time. Additionally, researchers are exploring magnesium-based bioresorbable scaffolds that offer improved mechanical strength and faster resorption, reducing concerns related to prolonged polymer presence in the arteries.Another major breakthrough is the incorporation of drug-eluting coatings that help prevent restenosis by releasing antiproliferative agents such as sirolimus or everolimus during the initial healing phase. These drug-eluting bioresorbable scaffolds have demonstrated promising clinical outcomes by reducing in-stent restenosis rates while ensuring optimal vascular healing. Furthermore, computational modeling and AI-driven optimization techniques are enhancing scaffold design, leading to thinner strut profiles and improved flexibility, which reduce complications such as scaffold thrombosis. As these technological advancements continue to refine BVS performance, the adoption of these next-generation devices is expected to accelerate in interventional cardiology.
Which Market Trends Are Driving Growth in the Bioresorbable Vascular Scaffolds Industry?
The increasing prevalence of coronary artery disease and the rising number of percutaneous coronary interventions (PCIs) are among the most significant trends fueling the growth of the bioresorbable vascular scaffold market. With cardiovascular diseases remaining the leading cause of mortality worldwide, healthcare providers are prioritizing innovative solutions that improve long-term patient outcomes. The demand for BVS is also being driven by a shift toward minimally invasive and patient-friendly interventions, where bioresorbable technology aligns with the broader goal of reducing long-term foreign material presence in the body.Another key trend shaping the market is the increasing regulatory support for bioresorbable scaffolds. While earlier-generation BVS faced concerns over scaffold thrombosis and suboptimal degradation rates, recent innovations in material science and clinical data have led to renewed interest from regulatory agencies and healthcare professionals. Additionally, the expansion of bioresorbable technology beyond coronary interventions - into peripheral artery disease (PAD) and other vascular conditions - is opening new market opportunities. As clinical trials continue to validate the benefits of BVS, and more next-generation devices receive regulatory approvals, the market is poised for significant expansion in both developed and emerging economies.
What Are the Key Growth Drivers Shaping the Future of the Bioresorbable Vascular Scaffolds Market?
The growth in the bioresorbable vascular scaffold market is driven by multiple factors, including technological advancements, increasing clinical adoption, and a growing emphasis on long-term patient outcomes. One of the primary growth drivers is the rising burden of cardiovascular diseases, which necessitates innovative and effective treatment options. As patient populations expand, particularly in aging demographics and high-risk groups, the demand for bioresorbable scaffolds is expected to increase.Another crucial driver shaping the market is the strong investment in research and development (R&D) by medical device companies and academic institutions. Continuous improvements in scaffold design, resorption kinetics, and drug-eluting capabilities are enhancing the clinical feasibility of BVS technology. Additionally, strategic collaborations between healthcare providers, medical institutions, and biotech firms are accelerating the commercialization of advanced bioresorbable scaffolds. The increasing adoption of value-based healthcare models, which prioritize long-term patient benefits over short-term procedural costs, is also expected to boost the demand for BVS. As these factors continue to drive innovation and adoption, bioresorbable vascular scaffolds are set to redefine the future of coronary and peripheral artery disease management, improving patient outcomes while reducing long-term healthcare costs.
Report Scope
The report analyzes the Bioresorbable Vascular Scaffolds market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Application (Peripheral Artery Application, Coronary Artery Application); End-Use (Hospitals End-Use, Ambulatory Care Centers (ACS) End-Use, Specialty Clinics End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Peripheral Artery Application segment, which is expected to reach US$376.9 Million by 2030 with a CAGR of a 8.6%. The Coronary Artery Application segment is also set to grow at 5.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $115.1 Million in 2024, and China, forecasted to grow at an impressive 11.5% CAGR to reach $136.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Bioresorbable Vascular Scaffolds Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bioresorbable Vascular Scaffolds Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Bioresorbable Vascular Scaffolds Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Cardiovascular, BD, Biotronik AG, Boston Scientific Corporation, Elixir Medical Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 34 Featured):
- Abbott Cardiovascular
- BD
- Biotronik AG
- Boston Scientific Corporation
- Elixir Medical Corporation
- Kyoto Medical Planning Co., Ltd
- Meril Life Sciences
- MicroPort
- Reva Medical Inc
- Shandong Huaan Biotechnology Co.,Ltd
- Terumo Interventional Systems
- W. L. Gore & Associates, Inc.
- Zeus Inc
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Cardiovascular
- BD
- Biotronik AG
- Boston Scientific Corporation
- Elixir Medical Corporation
- Kyoto Medical Planning Co., Ltd
- Meril Life Sciences
- MicroPort
- Reva Medical Inc
- Shandong Huaan Biotechnology Co.,Ltd
- Terumo Interventional Systems
- W. L. Gore & Associates, Inc.
- Zeus Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 265 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 422.5 Million |
| Forecasted Market Value ( USD | $ 640 Million |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
